Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06628921 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)

Study acronym: BEFREE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary and study completion dates: Oct 30, 2025 to Oct 30, 2026
    • Study sites: 0 to 1
    • Collaborators: 4 to 3
    • Study title shortened, about 3 words
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved. The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\_5)
Trial Details
NCT Number NCT06628921
Lead Sponsor University of Florence
Collaborators: Società Italiana per lo Studio delle Cefalee, Fondazione Policlinico Universitario Campus Bio-Medico, SISC RICe Group
Conditions
(from sponsor)		 Migraine
Related terms Headache, Migraine Disorders, Pain
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov